| Group (n± S.D.) |
Group-1 |
Group-2 |
Group-3 |
P value |
| Mean follow-up in months |
19.34 ±4.2 |
20.60 ±3.67 |
20.55 ±3.23 |
|
| Patient survival |
100 % |
100 % |
100 % |
1 |
| Graft survival |
100 % |
100 % |
93.3 % |
0.13 |
| Mean serum creatinine (mg/dL) |
|
| 1 month |
1.33 ±0.3 |
1.33 ±0.22 |
1.31 ±0.3 |
0.2 |
| 3 months |
1.32 ±0.3 |
1.33 ±0.19 |
1.22 ±0.25 |
0.21 |
| 6 months |
1.30 ±0.33 |
1.33 ±0.28 |
1.37 ±0.56 |
0.8 |
| 9 months |
1.29 ±0.32 |
1.37 ±0.46 |
1.25 ±0.23 |
0.46 |
| 12 months |
1.29 ±0.36 |
1.36 ±0.4 |
1.24 ±0.27 |
0.40 |
| 15 months |
1.15 ±0.29 |
1.28 ±0.21 |
1.27 ±0.36 |
0.49 |
| 18 months |
1.23 ±0.32 |
1.38 ±0.26 |
1.2 ±0.25 |
0.25 |
| Biopsy |
|
|
|
|
| AR <ag1 at1 av1 ai2 ptc 0 |
2 |
3 |
2 |
0.85 |
| ≥ ag1 at1 av1 ai2 ptc0 |
0 |
2 |
5 |
<0.01 |
| ≥cg1 ct1 cv1 ci2 ptc 0 |
0 |
0 |
1 |
0.36 |
| Tregs in peripheral blood |
| 3 months |
3.51 ± 0.55 |
3.28 ± 0.67 |
1.58 ± 0.62 |
<0.01 |
| 6 months |
3.12 ± 0.71 |
2.94 ± 0.7 |
1.43 ± 0.37 |
<0.01 |
| 9 months |
3.16 ± 1.14 |
2.93 ± 0.85 |
1.76 ± 1.07 |
<0.01 |
| 12 months |
3.09 ± 1.04 |
2.96 ± 1.18 |
1.84 ± 0.77 |
<0.01 |
| 15 months |
3.02 ± 0.44 |
2.98 ± 0.77 |
1.98 ± 0.93 |
<0.01 |
| 18 months |
3.52 ± 0.84 |
3.19 ± 0.49 |
2.09 ± 0.86 |
<0.01 |
| Two immunosuppressants |
30 (100%) |
28 (93.3%) |
0 |
<0.01 |
| Three immunosuppressants |
0 |
02 (6.7%) |
30 (100%) |
<0.01 |
|
